KT-413, a Novel IRAKIMiDDegrader of IRAK4 and IMiDSubstrates Case Study
KT-413, a Novel IRAKIMiDDegrader of IRAK4 and IMiDSubstrates Case Study
15 PagesSingle-agent therapies that target activated NFκB signaling in DLBCL show limited activity in preclinical or clinical settings. Redundant NFκB pathway activation and downregulation of Type 1 IFN is common in MYD88MTlymphoma, supporting need to seek combination therapies. Targeting simultaneous degradation of IRAK4 and IMiDsubstrates Ikarosand Aiolosshows synergistic activity in MYD88MT models, supporting this targeted combination.
